139 related articles for article (PubMed ID: 17136543)
1. Sunitinib malate.
Izzedine H; Buhaescu I; Rixe O; Deray G
Cancer Chemother Pharmacol; 2007 Aug; 60(3):357-64. PubMed ID: 17136543
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
Cabebe E; Wakelee H
Drugs Today (Barc); 2006 Jun; 42(6):387-98. PubMed ID: 16845442
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
5. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Polyzos A
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Papaetis GS; Syrigos KN
BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
[TBL] [Abstract][Full Text] [Related]
7. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.
George S
Curr Oncol Rep; 2007 Jul; 9(4):323-7. PubMed ID: 17588358
[TBL] [Abstract][Full Text] [Related]
9. New perspectives: role of sunitinib in breast cancer.
Fratto ME; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G
Clin Ter; 2010; 161(5):475-82. PubMed ID: 20949248
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for sunitinib efficacy and future clinical development.
Faivre S; Demetri G; Sargent W; Raymond E
Nat Rev Drug Discov; 2007 Sep; 6(9):734-45. PubMed ID: 17690708
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in the management of gastrointestinal stromal tumours (GISTs).
Hopkins TG; Marples M; Stark D
Eur J Surg Oncol; 2008 Aug; 34(8):844-850. PubMed ID: 18082353
[TBL] [Abstract][Full Text] [Related]
12. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
13. New perspectives: role of Sunitinib in breast cancer.
Fratto ME; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G
Clin Ter; 2011; 162(3):251-7. PubMed ID: 21717054
[TBL] [Abstract][Full Text] [Related]
14. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
Motzer RJ; Michaelson MD; Redman BG; Hudes GR; Wilding G; Figlin RA; Ginsberg MS; Kim ST; Baum CM; DePrimo SE; Li JZ; Bello CL; Theuer CP; George DJ; Rini BI
J Clin Oncol; 2006 Jan; 24(1):16-24. PubMed ID: 16330672
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib in the treatment of advanced solid tumors.
Imbulgoda A; Heng DY; Kollmannsberger C
Recent Results Cancer Res; 2014; 201():165-84. PubMed ID: 24756791
[TBL] [Abstract][Full Text] [Related]
16. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
17. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Norden-Zfoni A; Desai J; Manola J; Beaudry P; Force J; Maki R; Folkman J; Bello C; Baum C; DePrimo SE; Shalinsky DR; Demetri GD; Heymach JV
Clin Cancer Res; 2007 May; 13(9):2643-50. PubMed ID: 17473195
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Wu CL; Ping SY; Yu CP; Yu DS
Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.
Patyna S; Arrigoni C; Terron A; Kim TW; Heward JK; Vonderfecht SL; Denlinger R; Turnquist SE; Evering W
Toxicol Pathol; 2008 Dec; 36(7):905-16. PubMed ID: 18981453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
